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Abstract
Background. Paricalcitol and cinacalcet are common
therapies for patients on haemodialysis with secondary
hyperparathyroidism (SHPT). We conducted a multi-
centre study in 12 countries to compare the safety and
efficacy of paricalcitol and cinacalcet for the treatment
of SHPT.
Methods. Patients aged 18 years with Stage 5 chronic
kidney disease receiving maintenance haemodialysis and
with intact parathyroid hormone (iPTH) 300–800 pg/mL,
calcium 8.4–10.0 mg/dL (2.09–2.49 mmol/L) and phospho-
rus6.5 mg/dL (2.09 mmol/L) were randomized within two
strata defined by the mode of paricalcitol administration to
treatment with paricalcitol- (intra-venous, US and Russian
sites, IV stratum; oral, non-US and non-Russian sites, oral
stratum) or cinacalcet-centred therapy. The primary endpoint
is the proportion of patients in each treatment group who
achieve a mean iPTH value of 150–300 pg/mL during
Weeks 21–28 of treatment. Assuming efficacy response rates
of 36 and 66% for cinacalcet and paricalcitol, respectively,
and a 20% discontinuation rate, 124 subjects in each
stratum were estimated to provide 81% power to detect a
30% absolute difference in the primary endpoint.
Results. Of 746 patients screened, 272 (mean age, 63 years;
mean iPTH, 509 pg/mL) were randomized. Mean duration of
haemodialysis at baseline was 3.7 years. Comorbidities in-
cluded hypertension (90.4%), Type 2 diabetes (40.4%), con-
gestive heart failure (17.3%), coronary artery disease (34.6%)
and gastrointestinal disorders (75%).
Conclusions. The study participants are representative of
a multinational cohort of patients on haemodialysis with
elevated iPTH. The study results will provide valuable
information on the best available treatment of SHPT in
patients on haemodialysis.
Keywords: cinacalcet hydrochloride; haemodialysis;
hyperparathyroidism; kidney disease; paricalcitol
Introduction
Secondary hyperparathyroidism (SHPT) is a major compli-
cation of chronic kidney disease (CKD) [1] resulting from
impaired calcium and phosphate homeostasis and a lack of
vitamin D receptor (VDR) activation secondary to active
vitamin D deficiency [2, 3]. SHPT is characterized by
increased parathyroid hormone (PTH) synthesis and secre-
tion and progressive parathyroid gland hyperplasia [2].
Important pathogenic factors in SHPT include phosphate
retention, hypocalcaemia, low levels of active vitamin D
(1,25-dihydroxycholecalciferol, calcitriol) [3], high levels
of fibroblast growth factor 23 (FGF23) [4], parathyroid
resistance to inhibition by calcium, vitamin D [5] and
FGF23 [6, 7] and skeletal resistance to PTH [3].
Severe SHPT is associated with a high risk of unfavour-
able clinical outcomes, particularly cardiovascular compli-
cations [1, 8] and high-turnover metabolic bone disease [3].
A strong association between vitamin D deficiency and
cardiovascular disease is well established for the general
population [9] and for patients on haemodialysis [10].
Other risk factors for mortality in patients on haemodialysis
include hypocalcaemia, hyperphosphataemia [11] and high
FGF23 [12]. Control of the levels of intact PTH (iPTH),
calcium and phosphate is an important therapeutic goal in
treating patients with SHPT on haemodialysis. For patients
with Stage 5 CKD on haemodialysis, the 2003 guidelines
of the Kidney Disease Outcomes Quality Initiative
(KDOQI) of the National Kidney Foundation recommend
specific targets for these parameters, including serum iPTH
concentrations of 150–300 pg/mL [13]. In contrast, the
2009 Kidney Disease—Improving Global Outcomes
(KDIGO) guidelines recommend maintaining PTH
between two and nine times the upper limit of normal [14],
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which corresponds to a range of 130–600 pg/mL [15].
The KDIGO guidelines further recommend that a clinically
relevant trend towards marked increase (or decrease) in iPTH
levels should prompt initiation of or change in therapy to
avoid progression to levels outside of this range.
A variety of treatments for SHPT are currently available
including non-selective (calcitriol, alfacalcidol, doxercalci-
ferol) and selective VDR activators (paricalcitol and maxa-
calcitol) and the calcimimetic cinacalcet. Paricalcitol [16, 17]
is approved for the treatment of patients with SHPT with
Stages 3–5 of CKD, whereas cinacalcet [18] is approved
for the treatment of patients with SHPT on dialysis. A draw-
back of calcitriol and other non-selective VDR activators is
that high doses may cause hypercalcaemia [19], which is
associated with increased mortality in patients on haemodial-
ysis [20]. The risk of hypercalcaemia associated with VDR
activators can be reduced by using a selective VDR activator
such as paricalcitol, which causes lesser hypercalcaemia due
to smaller increases in intestinal calcium absorption than
other VDR activators [21–23], or by using cinacalcet, which
allosterically activates the calcium-sensing receptor to reduce
PTH secretion [19]. Adding cinacalcet to conventional care
or to low-dose VDR activator therapy in patients on haemo-
dialysis has been shown to reduce the serum levels of
calcium, phosphate, PTH [24–27] and FGF23 [28].
Randomized controlled studies also demonstrated that
intra-venous and oral paricalcitol effectively reduce iPTH
in patients with Stage 5 CKD without significantly increas-
ing the risk of hypercalcaemia or hyperphosphatemia
[29, 30]. Data from large observational studies suggest that
paricalcitol compared with calcitriol is associated with a
significantly lower risk of all-cause mortality [31] and that
increasing doses of paricalcitol per unit of serum PTH may
provide incremental survival benefits [32].
The purpose of this international, multi-centre, random-
ized controlled trial is to compare the safety and efficacy of
paricalcitol and cinacalcet for the treatment of SHPT in pa-
tients on haemodialysis. The primary outcome (iPTH
150–300 pg/mL) is based on the 2003 KDOQI guidelines;
the 2009 KDIGO guidelines for the management of CKD-
associated mineral and bone disorder [14] were not yet
available at the time this study was designed. In addition,
despite the recent KDIGO guidelines, much clinical prac-
tice still employs KDOQI recommendations. Here, we pro-
vide details of the study design and of the demographic and
baseline characteristics of the study population.
Materials and methods
Study design
The primary objective of this 28-week, multi-centre, randomized open-
label Phase 4 study (ClinicalTrials.gov identifier: NCT00977080) is to
compare the efficacy of paricalcitol-centred therapy and that of cinacal-
cet-centred therapy in achieving the KDOQI goal for iPTH in subjects on
haemodialysis with SHPT. The study design stipulates randomization and
separate analysis within two strata defined by the mode of paricalcitol
administration (intra-venous at US and Russian sites, IV stratum; oral at
non-US and non-Russian sites, oral stratum). The primary efficacy analy-
sis, conducted separately in each stratum, will compare the proportion
of patients in each treatment group who achieve a mean iPTH value of
150–300 pg/mL during Weeks 21–28 of the treatment period. Secondary
efficacy analyses will compare the proportions of patients who achieve at
least a 30 or 50% reduction from baseline in iPTH and the proportions with
a mean calcium <8.4 mg/dL (2.09 mmol/L) or >10.5 mg/dL (2.61 mmol/
L) during Weeks 21–28. Safety will be evaluated through adverse
events reporting and assessment of changes in complete chemistry
and haematology measurements and vital signs. Additional laboratory
tests will be conducted to assess changes in FGF23, bone-specific alka-
line phosphatase (BSAP), alkaline phosphatase, phosphate, PTH-
related peptide and 25-hydroxy vitamin D. Ibis testing, which combines
polymerase chain reaction and mass spectrometry to detect DNA in
biological samples, will be used to identify the presence of viral and
microbial pathogens [33].
For each study site, the protocol was approved by an Institutional Re-
view Board or Independent Ethics Committee. The study is being con-
ducted in accordance with the protocol, International Conference on
Harmonization guidelines, applicable regulations and guidelines govern-
ing clinical study conduct and the ethical principles established in the
Declaration of Helsinki. All study participants provided written informed
consent before undergoing any study-related procedures.
Enrolment has been completed. After an initial screening period, eligi-
ble participants underwent a 4-week washout period during which they
discontinued prior VDR activator and cinacalcet therapy and after which
they were re-evaluated for eligibility (Figure 1). A stratified randomization
scheme was used. Random assignment at a ratio of 1:1 to paricalcitol or
cinacalcet occurred within each of two strata defined by the mode of
paricalcitol administration (oral or intra-venous). The randomization
schedule was generated by the Clinical Statistics Department at Abbott
Laboratories (Abbott Park, IL) before the start of the study. Treatment
group assignment occurred at the Day 1 visit and was implemented
through an interactive voice response system.
Randomized patients receive one of two treatments for 28 weeks
(Figure 1). Patients assigned to paricalcitol will receive intra-venous
paricalcitol (US and Russian sites) or oral paricalcitol (non-US and non-
Russian sites). The mean absolute bioavailability of paricalcitol capsules
under low-fat diet conditions ranges from 72 to 86% in healthy subjects
and in CKD Stage 5 patients on haemodialysis.
In the paricalcitol arm, cinacalcet will be administered as supplemental
medication if serum calcium is 10.5 mg/dL (2.61 mmol/L) in samples of
two consecutive blood tests. Doses of paricalcitol will be adjusted as
shown in Figure 2. Patients assigned to the cinacalcet arm will receive
cinacalcet and intra-venous doxercalciferol 1.0 lg three times weekly (US
sites) or cinacalcet and oral alfacalcidol 0.25 lg/d (non-US sites). Planned
dose adjustments for cinacalcet are shown in Figure 3. Dose adjustments
will be based on chemistry results determined every 2 weeks until study
completion during Week 28 or early termination.
Study population
Eligible patients were aged 18 years with Stage 5 CKD who had been
receiving maintenance haemodialysis three times weekly for at least
3 months before screening and were to continue haemodialysis during
the study. At screening, eligible patients had to have a serum iPTH 130–
700 pg/mL, total alkaline phosphatase 40 U/L, calcium 10.0 mg/dL
(2.49 mmol/L) and calcium–phosphorus product (Ca 3 P) 75 mg2/dL2
Fig. 1. Study design. Paricalcitol arm: paricalcitol intra-venous (US and
Russian sites) or oral (non-US and non-Russian sites) with cinacalcet for
hypercalcaemia, if necessary. Cinacalcet arm: cinacalcet plus low-dose
vitamin D.
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for US centres or 70 mg2/dL2 for non-US centres (based on recommen-
dations in the prescribing information for the study drugs). Required pre-
randomization values were iPTH 300–800 pg/mL, calcium 8.4–10.0 mg/
dL (2.09–2.49 mmol/L) and phosphorus 6.5 mg/dL (2.09 mmol/L). Key
exclusion criteria were allergic reaction or significant sensitivity to any
study drug, an expected daily requirement of >2.0 g of oral elemental
calcium, previous parathyroidectomy, chronic gastrointestinal disorders,
clinically significant liver disease and use of known inhibitors or inducers
of cytochrome P450 3A or of drugs metabolized by cytochrome P450 2D6
within 2 weeks before study drug administration.
Fig. 2. Dose adjustments in the paricalcitol arm for sites inside (A) and outside (B) the USA and Russia. Ca, calcium; Ca 3 P, calcium–phosphorus
product. (Adherence to the dosing algorithms is mandatory unless the investigator feels there is a risk to subject safety.)
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Clinical trial simulations
Clinical trial simulations (Trial Simulator Version 2.2.1; Pharsight Corpo-
ration, Mountain View, CA) were performed to predict the efficacy of
paricalcitol with regard to the primary endpoint. The results of the simu-
lations justified the design of this comparative study and provided a basis
for statistical power estimation.
The simulations used parameter estimates from a proprietary paricalci-
tol population exposure–clinical response model to identify a study design
that would maximize safety and efficacy in meeting KDOQI targets for
iPTH while remaining consistent with prescribing information recommen-
dations for intra-venous (US and Russian sites) and oral (all other sites)
paricalcitol. Each simulated clinical trial included 200 subjects on haemo-
dialysis with SHPT who were randomized 1:1 to receive intra-venous or
oral paricalcitol or placebo administered three times weekly. Overall, five
simulated clinical trials were conducted, providing a total of 500 subjects
per treatment arm. All enrolled subjects were assumed to be fully com-
pliant with the assigned dosing and sampling schemes. The proportions of
subjects predicted to achieve a mean iPTH value of 150–300 pg/mL and a
mean calcium value of 8.4–10.5 mg/dL during Weeks 21–28 of treatment
were summarized as the average of the five replicated clinical trials. The
proportion of subjects experiencing two consecutive events of calcium
10.5 mg/dL also was predicted. These subjects would be eligible for
addition of cinacalcet.
Determination of sample size
A point estimate of 25% for the proportion of cinacalcet patients who achieve
the primary endpoint (an iPTH value of 150–300 pg/mL) was obtained from
published results of the ACHIEVE study [26]. The upper limit of an exact
95% confidence interval for the 25% point estimate of cinacalcet subjects
achieving the primary endpoint was 36%. Clinical trial simulation for par-
icalcitol-based therapy predicted an efficacy response rate 66% for the
primary endpoint. Assuming efficacy response rates of 36 and 66% for the
cinacalcet and paricalcitol groups, respectively, and allowing for a discontin-
uation rate of 20%, a sample size of 124 subjects per stratum was estimated
to provide 81% power, with a Fisher’s exact test at a 0.050 two-sided sig-
nificance level, to detect a 30% absolute difference between treatment groups
in the proportion of patients who reach the primary efficacy endpoint.
Statistical and analytical methods
Data were summarized for all randomized subjects. Quantitative demo-
graphic and baseline laboratory variables were summarized with mean and
SD. Rates and proportions were summarized with number of patients and
percentage. Correlations between baseline FGF23 and baseline age, iPTH,
calcium, phosphorus, alkaline phosphatase, BSAP, 25-hydroxy vitamin D
and albumin were evaluated using Spearman rank correlation coefficient.
iPTH was measured by IMMULITE chemiluminescent assay system
(Siemens, Deerfield, IL) with a linear range of 3–2500 pg/mL. FGF23 was
measured by an enzyme-linked immunosorbent assay for human intact FGF
23 (Immutopics, Inc., San Clemente, CA). Alkaline phosphatase concentra-
tions were determined by enzymatic assay using p-nitrophenyl phosphate
hydrolysis (Roche Diagnostics, Indianapolis, IN). BSAP was assayed after
immune capture with selective high-affinity antibodies (Microvue BAP
EIA kit; Quidel Corporation, San Diego, CA).
Patient-reported outcomes
To compare the effects of the two different treatments on kidney disease-
related quality of life (KDQOL), the study uses the KDQOL instrument,
which has been used extensively in the dialysis population [34–36]. The
KDQOL questionnaire includes 36 items (RAND-36; Rand Corporation,
Santa Monica, CA) identical to those included in the Short Form-36. Eight
scales of self-reported health status (physical function, role physical, bod-
ily pain, general health, vitality, social functioning, role emotional and
mental health) are scored 0–100, with higher scores indicate better func-
tion. Two normalized scores representing overall physical and mental
functioning are calculated by using the dimensions related to physical
and mental functioning, respectively. KDQOL also includes a symptom
score for several kidney disease-specific symptoms. In addition to
KDQOL, bone pain is assessed using a bone pain visual analogue scale
of 0–100 (with higher scores indicating worse pain). Patients are asked to
record their worst pain experienced in the past 4 weeks. Patients with
missing data for a specific analysis were excluded from that analysis.
Analyses were conducted using SAS Version 9.1 (SAS Institute, Inc.,
Cary, NC).
Results
Of 746 patients screened, 272 were enrolled in the study
(Table 1). Of 578 patients eligible before washout, 306
(53%) failed to meet eligibility criteria after washout. Most
of those who failed to enter the treatment phase had high
Fig. 3. Dose adjustments in the cinacalcet arm. Ca, calcium. (Adherence to the dosing algorithms is mandatory unless the investigator feels there is a risk
to subject safety.)
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(21%) or low (41%) iPTH levels or a low calcium level
(20%) (Table 1).
Study participants had a median age of 63.5 years, and
most participants were men (62.5%) (Table 2). Most par-
ticipants were white (73.5%) or black (21.3%). Mean du-
ration of dialysis was 3.7 years. Large majorities of patients
had comorbidities, including hypertension (90%) and gas-
trointestinal disorders (75%), of which gastroesophageal
reflux disease (18.4%) and nausea (17.6%) were the most
common. Consequently, patients were receiving a variety
of concomitant medications. Most patients (72.1%)
received erythropoiesis-stimulating agents. Mean iPTH
serum concentration was 509 pg/mL (Table 3). Participants
showed substantial variations in vitamin D, FGF23 and
BSAP levels (Table 3). A univariable analysis demonstra-
ted highly significant correlations of FGF23 levels with
those of iPTH, calcium, phosphorus and bone-specific
phosphatase (Table 4). Scores for most patient-reported
outcomes were similar for different racial groups; however,
white compared with black patients had higher mean scores
for work status, patient satisfaction and bone pain (visual
analogue scale) and lower mean scores for effects and bur-
den of kidney disease, cognitive function, quality of social
interaction, sexual function, physical role limitations, pain,
general health and emotional well-being. The overall mean
scores for the majority of patient-reported outcomes (Table
5) were higher than those previously published for a global
population with end-stage renal disease [37].
Discussion
The purpose of our study is to compare the efficacy of
paricalcitol- versus cinacalcet-centred therapy in maintain-
ing KDOQI targets for iPTH, calcium and phosphate in
subjects on haemodialysis [13]. The doses selected for
the study drugs are consistent with those indicated for dial-
ysis patients with SHPT in the package inserts for parical-
citol injection [17], paricalcitol capsules [16] and cinacalcet
tablets/capsules [18]. The doses of doxercalciferol and al-
facalcidol are based on the dose equivalencies previously
suggested for low-dose VDR activators in the ACHIEVE
study [26].
Our clinical trial simulations predicted that a study
duration of 28 weeks with a 4-week washout period will
allow a majority of subjects in the paricalcitol arms to
achieve a PTH value of 150–300 pg/mL and the KDOQI
target for calcium. Approximately 85–95% of participants
receiving paricalcitol are expected to complete the study
without requiring cinacalcet supplementation for hypercal-
caemia and >90% are predicted to maintain serum calcium
of 8.5–10.5 mg/dL during the assessment phase.
Table 1. Screening/washout failures
Screen failures, n (%) Washout failures, n (%)
Total entering screening 746 (100) Total entering washout 578 (77)
Excluded after screening 168 (23) Excluded after washout 306 (53)
Reason for failure Reason for failure
iPTH > 700 pg/mL 48 (29) iPTH > 800 pg/mL 65 (21)
iPTH < 130 pg/mL 39 (23) iPTH < 300 pg/mL 124 (41)
Calcium > 10.0 mg/dL 46 (27) Calcium > 10 mg/dL 22 (7)
Ca 3 P > 75 mg2/dL2 (US) or > 70 mg2/dL2 (non-US) 19 (11) Calcium < 8.4 mg/dL 61 (20)
Serum alkaline phosphatase < 40 U/L 21 (13) Phosphorus > 6.5 mg/dL 61 (20)
Ca 3 P, calcium–phosphorus product.
Table 2. Demographic and baseline characteristicsa
Characteristicb
Total study
population
(N ¼ 272)
Age, years
Mean 6 SD 62.9 6 12.9
Median (range) 63.5 (22.0–97.0)
Females 102 (37.5)
Race
White 200 (73.5)
Black 58 (21.3)
Asian 6 (2.2)
Other 8 (2.9)
Medical history
Hypertension 246 (90.4)
Diabetes mellitus Type 1 10 (3.7)
Diabetes mellitus Type 2 110 (40.4)
Congestive heart failure 47 (17.3)
Coronary artery disease 94 (34.6)
Cerebral vascular accident 24 (8.8)
Gastrointestinal disorders 204 (75.0)
Duration of dialysis, years, mean 6 SD 3.7 6 3.4
Blood pressure, mean 6 SD
Systolic, mmHg 140.4 6 23.2
Diastolic, mmHg 73.4 6 13.6
Concomitant medication history
Phosphate binders
Calcium containing
Calcium acetate 62 (22.8)
Calcium carbonate 38 (14.0)
Non-calcium containing
Lanthanum 47 (17.3)
Sevelamer 131 (48.2)
Anti-hypertensives
ACE inhibitors 65 (23.9)
Angiotensin II receptor blockers 47 (17.3)
Beta blockers 131 (48.2)
Calcium channel blockers 97 (35.7)
Diuretics 66 (24.3)
Anti-adrenergic, central 27 (9.9)
Anti-adrenergic, peripheral 21 (7.7)
Erythropoiesis-stimulating agents 196 (72.1)
Neuropsychiatric 88 (32.4)
aACE, angiotensin-converting enzyme.
bValues shown are n (%) unless otherwise specified.
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The safety and efficacy of paricalcitol in the treatment of
SHPT are well established, and observational studies have
shown that VDR activators may be associated with im-
proved survival [31, 38, 39]. Similarly, results of a large
retrospective data analysis suggest that treatment of pa-
tients on haemodialysis with cinacalcet is associated with
a significant reduction in all-cause and cardiovascular mor-
tality [40]. This prospective study is the first that uses
maximized and pre-specified doses in a direct comparison
of the safety and efficacy of these two primary approaches
to SHPT therapy in patients on haemodialysis. However,
this study will not provide information regarding the long-
term outcomes associated with each treatment.
The study has a number of secondary objectives. Of par-
ticular importance is the evaluation of changes in bone and
mineral metabolic markers to gain a better understanding of
the differential effects of paricalcitol- and cinacalcet-centred
therapies on these markers. In a 3-year cohort study of
73 960 patients on haemodialysis, high serum concentrations
of alkaline phosphatase, particularly those >120 U/L, were
associated with increased risk of all-cause mortality [41].
Correlation analyses further suggest that elevated serum al-
kaline phosphatase is associated with low bone mineral den-
sity [42] and increased coronary artery calcification [43] in
these patients. KDIGO has recommended monitoring BSAP
in patients with CKD for the diagnostic evaluation
of metabolic bone disease [14, 15]. Results of placebo-
controlled Phase 3 studies have provided evidence that both
paricalcitol and cinacalcet significantly reduce BSAP in
patients with SHPT on dialysis [24, 30].
FGF23 is a key regulator of phosphate homeostasis that
reaches extremely high circulating concentrations in pa-
tients with end-stage renal disease [4]. High levels of
FGF23 were associated independently with increased risk
of death in patients beginning haemodialysis [12] and
with cardiovascular events in patients with pre-dialysis
CKD [44]. VDR activators have been shown to increase
Table 3. Baseline laboratory values
Total study population (N ¼ 272)
Variable Mean 6 SD
Median
(range)
25-hydroxy vitamin D, ng/mL 19.2 6 10.8 16.5 (7.0–57.0)
Corrected calcium, mg/dL 9.0 6 0.6 9.0 (5.1–10.8)
Phosphorus, mg/dL 4.8 6 1.1 4.7 (1.3–9.3)
Serum iPTH, pg/mL 509.0 6 147.7 488.0 (130.0–794.0)
Fibroblast growth
factor 23, pg/mL
375.8 6 551.2 146.3 (8.0–4418.8)
Alkaline phosphatase, IU/L 110.0 6 46.6 100.0 (34.0–368.0)
BSAP, U/L 41.6 6 24.5 35.9 (3.3–274.0)
Creatinine, mg/dL 8.6 6 2.6 8.5 (2.7–16.7)
Albumin, g/dL 4.1 6 0.3 4.1 (2.7–4.7)
Table 4. Correlation between FGF23 and continuous baseline variables
Predictor variable
Spearman correlation
coefficient P-value
Age, years 0.1479 0.024
iPTH 0.2161 <0.001
Calcium 0.3431 <0.001
Phosphorous 0.4944 <0.001
Alkaline phosphatase 0.1339 0.041
BSAP 0.2074 0.001
25-hydroxy vitamin D 0.0284 0.703
Albumin 0.0460 0.485
Table 5. Baseline patient-reported outcomes scores
Scale, variable Score, mean 6 SD n
Score by race, mean 6 SD
White Black Other
KDQOL
Symptoms/problems 79.4 6 14.5 256 79 6 14.6 80.8 6 12.1 80 6 21
Effects of kidney disease 69.8 6 21.2 256 68.1 6 21.8 75.1 6 15.1 73.5 6 29
Burden of kidney disease 45.9 6 27 255 43.4 6 26.5 55 6 26.7 45.2 6 29.2
Work status 25.8 6 32.7 250 27.2 6 33.4 18.3 6 28.1 35.7 6 36.3
Cognitive function 77.4 6 26.9 256 74.6 6 28.8 87.2 6 14.7 77.6 6 28
Quality of social interaction 76.7 6 25.6 257 73.6 6 27.8 87 6 13.8 79 6 19.4
Sexual function 70.3 6 32.8 116 67.7 6 33 80 6 29.8 66.1 6 38.7
Sleep 64 6 19.8 256 63.9 6 21.1 63.6 6 14.9 67.3 6 17.6
Social support 77.3 6 26.4 254 76 6 27.5 82.7 6 20.3 75 6 29.8
Dialysis staff encouragement 81.4 6 19.6 256 82.1 6 20.2 80 6 16.3 76.8 6 23.4
Overall health rating 59.4 6 19.4 253 58.6 6 19.6 59.6 6 17.7 70 6 20.8
Patient satisfaction rating 75.6 6 19 255 77.7 6 18.3 70.1 6 18.6 66.7 6 23.6
Physical composite score 37.5 6 10.7 253 37.1 6 10.9 38.2 6 9.6 39.6 6 11.2
Mental composite score 51.7 6 10.4 253 51.3 6 10.6 53.5 6 9.8 50.8 6 10.2
Physical functioning 55.7 6 28.6 257 55.7 6 29.2 53.6 6 26.6 63.9 6 29.1
Role limitations, physical 51.1 6 43.3 255 48.4 6 42.8 55.5 6 44 71.4 6 43.7
Pain 67.6 6 26.4 256 65.7 6 27.5 75.8 6 20.5 61.6 6 26.3
General health 47.3 6 21.1 257 46.4 6 21.6 51.2 6 19.7 45.4 6 18.7
Emotional well-being 75.7 6 20.1 256 74.4 6 20.3 81.4 6 17.7 72 6 23.5
Role limitations, emotional 72.7 6 39.8 255 71.3 6 40.2 73.6 6 40.5 88.1 6 28.1
Social function 74.9 6 25.3 257 75.2 6 25.7 76.2 6 23 65.2 6 27.8
Energy/fatigue 53.1 6 23.4 257 52.5 6 23.9 54.5 6 21.8 56.9 6 22.5
Bone pain visual analogue scale 27.1 6 27.9 248 29.1 6 28.5 21.2 6 26 20.3 6 22.2
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FGF23 levels in vitro [45]. In addition, results from a recent
prospective clinical study showed that treatment with cal-
citriol or doxercalciferol increased FGF23 by a factor of 4
in dialysis patients with SHPT [46]. In contrast, cinacalcet
has been shown to reduce FGF23 in such patients, even if
they receive low-dose VDR activators at the same time
[28]. However, despite the increase in FGF23 associated
with VDR activator therapy, results of epidemiological
studies consistently suggested that such therapy provides
survival benefits for patients on haemodialysis [47], at least
some of which appear to be independent of effects on cal-
cium, phosphate and iPTH [31]. Correlation analyses of
baseline data from our study suggest that PTH, calcium,
phosphorus and BSAP levels each are associated with
FGF23 levels in subjects on haemodialysis. Although the
results of this study may help to identify the FGF23
response to different therapeutic strategies for controlling
SHPT, the significance of changes in FGF23 associated
with various therapies remains to be determined. Other
important secondary objectives include the comparison of
patient-reported outcomes (e.g. pain and quality of life) and
costs associated with each treatment regimen.
Recruitment for this study was characterized by a high
degree of screening and washout failures, suggesting wide
intra-subject fluctuations in iPTH and calcium levels. Sig-
nificant intra-individual variance in iPTH and other
markers of bone mineral metabolism has been observed
previously in patients on haemodialysis [48]. After discon-
tinuing treatment for SHPT, a large percentage (41%) of
patients in our study did not experience the increase in
iPTH necessary to meet the eligibility criterion for entering
the treatment phase. The frequently observed decrease in
calcium was most likely secondary to discontinuation of
VDR activator therapy.
Participants are mostly older subjects with significant co-
morbidities, particularly hypertension, diabetes and cardi-
ovascular disease, who require a variety of concomitant
medications, thus representing a cohort of real-life patients
with CKD on haemodialysis. Participants include a large
percentage of female and non-white patients, reflecting ap-
propriate gender balance and ethnic diversity in this multi-
national study. Apart from the inclusion criteria, patients
showed substantial variation in laboratory parameters, par-
ticularly vitamin D, FGF23 and BSAP. Therefore, the
results of this study are likely to be applicable to a diverse
population of subjects with SHPT on haemodialysis.
Conclusion
This ongoing study comparing the efficacy and safety of
paricalcitol and cinacalcet in an international diverse study
population will provide valuable information to determine
the best available treatment for achieving biochemical con-
trol of SHPT in patients on haemodialysis. Planned analyses
of bone and mineral metabolic markers such as FGF23,
alkaline phosphatase, BSAP, calcium and phosphorus are
expected to provide further information regarding the effects
of the different treatments on these markers. In addition, the
study will provide information for each treatment regarding
its costs and effects on patient-reported outcomes.
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